Latest News
Plexus, SunPower fall; Progress Software, Masonite International rise, Wednesday, 1/17/2024
Stocks that traded heavily or had substantial price changes on Wednesday: Plexus, SunPower fall; Progress Software, Masonite International rise
4 Magnificent Healthcare Stocks to Buy in 2024 and Beyond
Healthcare stocks have underperformed in 2023, but that is expected to change this year.
Positive Topline Results Reported from Bristol Myers Squibb's Phase 3 CheckMate-67T Trial of Subcutaneous Nivolumab with Halozyme's ENHANZE® Drug Delivery Technology for Advanced or Metastatic Clear Cell Renal Cell Carcinoma
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Bristol Myers Squibb (BMS) reported positive topline results from...
Update: Halozyme Announces Presentation of Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery at 13th Annual PODD: Partnership Opportunities in Drug Delivery Conference
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") will present the positive results of a clinical study demonstrating subcutaneous...
Halozyme Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the approval of Roche's Tecentriq® SC (atezolizumab), using Halozyme's...
Following a tumultuous performance year, the biotechnology sector is steadily regaining traction once again, with investors starting to reveal a somewhat bullish sentiment despite having to endure macroeconomic headwinds throughout the first half of the year. While there may be some indication that biotech companies are dusting off the dust...
HALOZYME REPORTS SECOND QUARTER 2023 FINANCIAL AND OPERATING RESULTS
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme" or the "Company") today reported its financial and operating results for the second...
Halozyme To Report Second Quarter 2023 Financial and Operating Results
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2023 financial and operating results...
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx reported positive topline data from the ADHERE study...
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Roche's Phase 3 OCARINA II trial evaluating OCREVUS® (ocrelizumab)...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that argenx received U.S. Food and Drug Administration (FDA) approval...
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will...
HALOZYME REPORTS FIRST QUARTER 2023 FINANCIAL AND OPERATING RESULTS
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today reported its financial and operating results for the first quarter ended March...
Halozyme to Present at Upcoming Investor Conferences
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is...
Halozyme To Report First Quarter 2023 Financial and Operating Results
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2023 financial and operating results...
Halo Collective Announces Management Cease Trade Order
/CNW/ - Halo Collective Inc. ("Halo" or the "Corporation") (NEO: HALO) (OTCQB: HCANF) (FSE: A9K0) a vertical integrated cannabis company, announced today that...
HALOZYME PROVIDES UPDATE ON LICENSEE CO-FORMULATION PATENT HEARING IN EUROPE
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today provides an update on a decision by the Opposition Division of the European...
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL AND OPERATING RESULTS
Fourth Quarter Revenue Increased 78% YOY to $181 million; GAAP Diluted Earnings per Share of $0.42 and Non-GAAP Diluted Earnings per Share of $0.481 Full Year...
Halozyme Appoints Barbara Duncan to its Board of Directors
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced the appointment of Barbara Duncan to its Board of Directors. Ms. Duncan...
HALOZYME THERAPEUTICS, INC. ANNOUNCES REDEMPTION OF 1.25% CONVERTIBLE SENIOR NOTES DUE 2024
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that it has elected to redeem on March 17, 2023 (the "Redemption Date")...
Halozyme Provides 2023 Financial Guidance and Outlook
/PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced its 2023 financial guidance and commented on its outlook for the upcoming year....
Halo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
/CNW/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) reports highest selling quarter and continues planned...
Halo Collective Reports Highest Selling Quarter for Budega Retail Locations and Plans to Continue Expansion
/PRNewswire/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) reports highest selling quarter and continues planned...
Halo Collective Reports Third Quarter 2022 Financial Results
/CNW/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) today announces its financial and operational results for the...
Halo Collective Enters into Convertible Promissory Note for Aggregate Principal Amount of Up To C$5 Million
/CNW/ - Halo Collective Inc. ("Halo" or the "Company") (NEO: HALO) (OTCQB: HCANF) (Germany: A9KN) today announced that it has entered into a promissory note...